Assistive, Neurostim Devices Get 'Patient Preference' Attention From US FDA
The agency's patient-preference initiative is expanding with a new workshop that will unite FDA lab staff and patients to discuss patient perspectives on assistive and neurological stimulation devices.
You may also be interested in...
The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.
The US FDA has approved additional indications for Thermo Fisher Scientific’s Oncomine Dx Target, allowing the companion diagnostic to be used to detect more varieties of lung and thyroid cancer.